Cytokine polymorphisms and genotypic susceptibility of HCV infection in ribavirin response to peg interferon

被引:1
|
作者
Mohammad, Y. A. [1 ]
Mohammed, A. [1 ]
Muath, S. [1 ]
机构
[1] King Khalid Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Abha 61413, Saudi Arabia
关键词
HCV genotypes; cytokines; polymorphisms; ribavirin; peg interferon; HEPATITIS-C VIRUS; IL28B POLYMORPHISM; GENE POLYMORPHISM; EPIDEMIOLOGY; ASSOCIATION; FIBROSIS; THERAPY; IMPACT; IL-10; RISK;
D O I
10.47665/tb.40.3.009
中图分类号
R38 [医学寄生虫学]; Q [生物科学];
学科分类号
07 ; 0710 ; 09 ; 100103 ;
摘要
Immune responses are largely regulated by cytokines. Genetic polymorphisms of the regulatory coding regions are recognized to impact the expression of cytokines. The abnormal cytokine levels in hepatitis C virus (HCV) infection seems to be involved in disease progression, viral survival, and therapeutic response. The current study assesses the polymorphisms associated with IL-6, IL-10, IL28B, IFN-gamma, TGF-beta, and TNF-alpha on the genotypic susceptibility to HCV infection and Ribavirin response to Peg interferon. Droplet digital polymerase chain reaction (PCR) was used to assess the gene polymorphisms associated with IL-6 A/G (rs2069837), IL-10-1082 G/A (rs1800896)], IL28B C/T (rs12979860), IFN-gamma +874 A/T (rs2430561), TGF-beta 1-509 C/T (rs1800469) and TNF-alpha-308 G/A promoter (rs1800629) from stored samples of 200 healthy individuals and 300 HCV infected patients. There was a significant association of AG and AA genotypes of IL28B, IFN-gamma, TGF-beta 1, and TNF-alpha over HCV susceptibility and treatment outcome. However, no association between IL-6 and IL-10 gene polymorphism to HCV susceptibility response to the treatment. The observations indicate IL28B CT, TGF-beta 1 CT, TT and TNF- AG with AA genotypes influence the cytokine expression, which is related to susceptibility and resistance to HCV infection and combined antiviral therapy.
引用
收藏
页码:331 / 336
页数:6
相关论文
共 50 条
  • [1] Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?
    Di Marco, Vito
    D'Ambrosio, Roberta
    Bronte, Fabrizio
    Saracco, Giorgio
    Lanza, Alfonso Galeota
    Forni, Gianluca
    Poggiali, Erika
    Calvaruso, Vincenza
    DIGESTIVE AND LIVER DISEASE, 2016, 48 (06) : 650 - 655
  • [2] Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse
    Lagging, Martin
    Rembeck, Karolina
    Buhl, Mads Rauning
    Christensen, Peer
    Dalgard, Olav
    Farkkila, Martti
    Hellstrand, Kristoffer
    Langeland, Nina
    Lindh, Magnus
    Westin, Johan
    Norkrans, Gunnar
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2013, 48 (07) : 839 - 847
  • [3] MBL2 Genetic Variants in HCV Infection Susceptibility, Spontaneous Viral Clearance and Pegylated Interferon Plus Ribavirin Treatment Response
    Zupin, L.
    Polesello, V.
    Alberi, G.
    Moratelli, G.
    Croce, S. L.
    Masutti, F.
    Pozzato, G.
    Crovella, S.
    Segat, L.
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2016, 84 (01) : 61 - 69
  • [4] Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:: A randomized controlled trial
    Di Marco, Vito
    Almasio, Piero Luigi
    Ferraro, Donatella
    Calvaruso, Vincenza
    Alaimo, Giuseppe
    Peralta, Sergio
    Di Stefano, Rosa
    Craxi, Antonio
    JOURNAL OF HEPATOLOGY, 2007, 47 (04) : 484 - 491
  • [5] The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C
    Behnava, Bita
    Sharafi, Heidar
    Keshvari, Maryam
    Pouryasin, Ali
    Mehrnoush, Leila
    Salimi, Shima
    Elizee, Pegah Karimi
    Ghazimoghaddam, Mehran
    Alavian, Seyed Moayed
    HEPATITIS MONTHLY, 2016, 16 (01)
  • [6] Relationship between γ-interferon gene polymorphisms and susceptibility to brucellosis infection
    Eskandari-Nasab, Ebrahim
    Moghadampour, Mehdi
    Hasani, Seyed-Shahaboddin
    Hadadi-fishani, Mehdi
    Mirghanizadeh-Bafghi, Seyyed-Ali
    Asadi-Saghandi, Abolghasem
    Zare, Fateme
    Sadeghi-Kalani, Behrooz
    Ghazali-bina, Mehran
    MICROBIOLOGY AND IMMUNOLOGY, 2013, 57 (11) : 785 - 791
  • [7] Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin
    A. Andriulli
    A. Iacobellis
    M. R. Valvano
    F. Spirito
    A. Ippolito
    F. Bossa
    F. Terracciano
    R. Fontana
    G. Niro
    Digestive Diseases and Sciences, 2013, 58 : 1371 - 1382
  • [8] Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin
    Andriulli, A.
    Iacobellis, A.
    Valvano, M. R.
    Spirito, F.
    Ippolito, A.
    Bossa, F.
    Terracciano, F.
    Fontana, R.
    Niro, G.
    DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (05) : 1371 - 1382
  • [9] Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin
    Andriulli, A.
    Cursaro, C.
    Cozzolongo, R.
    Iacobellis, A.
    Valvano, M. R.
    Mangia, A.
    Minerva, N.
    Bacca, D.
    Stanzione, M.
    Scuteri, A.
    Montalto, G.
    Andreone, P.
    JOURNAL OF VIRAL HEPATITIS, 2009, 16 (01) : 28 - 35
  • [10] HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy
    Hayes, C. Nelson
    Kobayashi, Mariko
    Akuta, Norio
    Suzuki, Fumitaka
    Kumada, Hiromitsu
    Abe, Hiromi
    Miki, Daiki
    Imamura, Michio
    Ochi, Hidenori
    Kamatani, Naoyuki
    Nakamura, Yusuke
    Chayama, Kazuaki
    GUT, 2011, 60 (02) : 261 - 267